Brief: Kubota Pharmaceutical Holdings unit and SIRION Biotech set sights on gene delivery tools for ocular gene therapy

Kubota Pharmaceutical Holdings

09/01/2018 02:31

Jan 9 (Reuters) - Kubota Pharmaceutical Holdings Co Ltd 
 4596.T   
    
    * Says co's wholly owned unit Acucela Inc signed a two-year 
development agreement with gene delivery expert SIRION Biotech 
GmbH (SIRION) to establish optimized AAV vectors for clinical 
applications in ocular gene therapy 
    * Says Acucela bolsters its move into the fast growing gene 
therapy market to find a genetic cure for retinitis pigmentosa 
    * Key terms of the agreement include milestone payments to 
SIRION, 
with additional royalties to be paid on net sales from resulting 
products or therapies 
 
    Source text in Japanese: https://goo.gl/n8VbQu 
    Further company coverage: 4596.T  
 
 (Beijing Headline News) 
 ((Beijing.HeadlineNews@thomsonreuters.com; +86 010 62674724; 
Reuters Messaging: Tingting.liu@thomsonreuters.com@reuters.net))